The efficacy of angiotensin II receptors’ blockers use in patients wkth arterial hypertension and metabolic syndrome


A.G. Evdokimova, E.V. Kovalenko, V.V. Evdokimov, K.I. Tebloev

A.I. Yevdokimov Moscow state university of medicine and dentistry of the Ministry of Health of Russia, Moscow
Article contains the results of effective use of a new sartanes representative of arterial hypertension in combination with metabolic syndrome. research works it induced the increase of glucose tolerance and insulin sensitivity, increase ofPPAR-γand adiponectin expression, inhibited albuminuria and proteinuria progression, supressed vessel wall cells proliferation.
Keywords: blockers of angiotenzin receptor, antihypertensive therapy, arterial hypertension
Read entire article

Literature

  • Муромцева Г.А., Концевая А.В., Константинов В.В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012–2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваск. терапия и профилакт. 2014;13(6):4-11. [Muromtzeva G.A., Kontzevaya A.V., Konstantinov V.V. and others. Prevalence of risk factors of noncontagious diseases in Russian population in 2012–2013. Results of ESSE-RF research. Cardiovascular therapy and prevention. 2014;13(6):4-11.].
  • Клинические рекомендации «Диагностика и лечение артериальной гипертензии» Российского медицинского общества по артериальной гипертонии, 2013. Кардиологическийвестник. 2015;10(1). [Clinical recommendations “Diagnostics and treatment of arterial hypertension” from Russian medical society on arterial hypertension, 2013. Bulletin of cardiology. 2015;10(1).]
  • Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями. Кардиологический Вестник. 2014;1:4-57. [Recommendations for curation of patients with arterial hypertension and metabolic disorders. Bulletin of cardiology. 2014;1:4-57.]
  • Xie X., Atkins E., Lv J.,Bennett A., Neal B., Ninomiya T., Woodward M., MacMahon S., Turnbull F., Hillis G.S., Chalmers J., Mant J., Salam A., Rahimi K., Perkovic V., Rodgers A.Effects of intensive blood pressure lowering on cardiovascular and renal outcomes:updated systematic review and meta-analysis. Lancet. 2016;387(10017):435-43.
  • Caballero A.E. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes. Res. 2003;11:1278–89.
  • Rabmouni K., Correia M.L.G., Haynes W.G., Mark A.L. Obesity –associated Hypertension. New insights into mechanisms. Hypertension. 2005;45:9–14.
  • Carey R.M., Siragy H.M. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr. Rev. 2003;24(3):261-71.
  • Cheung B.M. The new cardiovascular continuum. Hong Kong Med. J.2006;12(2):161-3.
  • Дедов И.И., Шестакова М.Н. Диабетическая нефропатия. М.: Универсум Паблишинг, 2000.240 с. [DedovI.I., ShestakovaM.N. Diabeticnephropathy. M.:Universum Publishing, 2000. P. 240.]
  • Евдокимова А.Г., Рыжова Ю.В.Современные аспекты антигипертензивной терапиис позиций кардио- и нефропротективного воздействия. Антибиотикиихимиотерапия. 2015;5-6:34-41.[Evdokimova A.G., Ryzhova Ju.V. Modern aspects of antihypertensive therapy from the viewpoint of cardio-and nephroprotective action. Antibiotics and chemotherapy. 2015;5-6:34-41.]
  • Matchar D.B., McCrory D.C., Orlando L.A.,Patel M.R., Patel U.D., Patwardhan M.B., Powers B., Samsa G.P., Gray R.N. Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension. Ann. Intern. Med. 2008;148:16-29.
  • Kobori H., Nangaku M., Navar L.G., Nishiyama A. The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease. Pharmacol. Rev. 2007;59(3):251-87.
  • Engeli S., Gorzelniak K., Kreutz R.,Runkel N., Distler A., Sharma A.M. Co-expression of reninangiotensin system genes in human adipose tissue. J. Hypertens. 1999;17:555–60.
  • Кисляк О.А., Похильченко М.В.Дополнительные возможности антигипертензивной терапии при метаболическом синдроме. Системныегипертензии. 2013;2:41-6.[Kislyak O.A., Pochilchenko M.V. Additional possibilities of antihypertensive therapy in case of metabolic syndrome. Systemic hypertensions. 2013;2:41-6.]
  • Ferre P. The biology of peroxisome proliferator-activated receptors. Relationship with lipid metabolism and insulin sensitivity. Diabetes. 2004;53:43-50.
  • Sample R.K., Krishna V., Chatterjee K., O’Rahilly S. PPARγ and human metabolic disease. J. Clin. Invest. 2006;116(3):581-9.
  • Kurtz T., Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens. Res. 2009;32 (10):826-34.
  • Clasen R., Schupp M., Foryst-Ludwig A.,Sprang C., Clemenz M., Krikov M., Thöne-Reineke C., Unger T., Kintscher U. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension. 2005;46(1):137-43.
  • Lindholm L., Ibsen H., Dahlöf B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristiansson K., Lederballe-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel H., Aurup P., Edelman J., Snapinn S.; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertenstion study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-10.
  • Кобалава Ж.Д. Ранний, стабильный контроль АД – гарант улучшения прогноза при артериальной гипертонии высокого риска: результаты мегаисследования VALUE. РМЖ. 2004;15.[Kobalava Zh.D. Early, stable control of arterial pressure - guarantee of improving the prognosis of high risk arterial hypertension: results of VALUE megaresearch work. RMJ.2004;15.]
  • Julius S., Kjeldsen S.E., Weber M., for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:2022-31.
  • Pfeffer M.A., Swedberg K., Grander C.B., Held P., McMurray J.J., Michelson E.L., Olofsson B., Ostergren J., Yusuf S., Pocock S.; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet. 2003;362:759-66.
  • Grander C.B., McMurray J.J., Yusuf S., Held P., Michelson E.L., Olofsson B., Ostergren J., Pfeffer M.A., Swedberg K.; CHARM Investigators and Committees.Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitоrs: the CHARM-Alternative trial. Lancet. 2003;362:772-6.
  • McMurray J.J., Оstergren J., Swedberg K., Granger C.B., Held P., Michelson E.L., Olofsson B., Yusuf S., Pfeffer M.A.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE inhibitor: the CHARM-Added trial. Lancet. 2003;362:767-71.
  • Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., Olofsson B., Ostergren J.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left ventricular systolic function: the CHARMPreserved trial. Lancet. 2003;362:777-81.
  • Lindholm L.H., Persson M., Alaupovic P., Carlberg B. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J. Hypertens. 2003;21(8):1563-74.
  • Elliott W., Meyer P. Incidence diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201-7.
  • Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Ritz E., Atkins R.C., Rohde R., Raz I.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001;345:851-60.


    • About the Autors

    Anna G. Evdokimova, MD, professor of the Department of hospital therapy № 2, A.I. Yevdokimov Moscow state university of medicine and dentistry of the Ministry of Health of Russia. Address: 127473, Moscow. 20/1 Delegatskaya St. Tel.:+74956096700. E-mail:aevdokimova@rambler.ru

    Yelena V. Kovalenko, PhD, associate professor of the Department of hospital therapy № 2, A.I. Yevdokimov Moscow state university of medicine and dentistry of the Ministry of Health of Russia. Address: 127473, Moscow. 20/1 Delegatskaya St. Tel.: +74956096700

    Vladimir V. Evdokimov, PhD, associate professor of the Department of hospital therapy № 2, A.I. Yevdokimov Moscow state university of medicine and dentistry of the Ministry of Health of Russia. Address: 127473, Moscow. 20/1 Delegatskaya St. Tel.:+74956096700

    Konstantin I. Tebloev, MD, professor, head of the Department of hospital therapy № 2, A.I. Yevdokimov Moscow state university of medicine and dentistry of the Ministry of Health of Russia. Address: 127473, Moscow. 20/1 Delegatskaya St. Tel.:+74956096700


    Similar Articles

    Back to Content

    Бионика Медиа